Background: Fistulae and stenoses represent frequent and severe complications in patients with Crohn disease (CD). Our study aimed to identify risk factors for fistula and stenosis formation in CD patients. Summary: We retrieved data of 1,600 CD patients from the nationwide Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). The risk for fistulae and stenoses in relation to gender, age at diagnosis, smoking status at diagnosis, and ileal involvement at diagnosis were analyzed. In the multivariate analysis, female gender showed a lower risk for developing perianal and any fistula (risk ratio [RR] 0.721, 95% confidence interval [CI] 0.582-0.893, p = 0.003 and RR 0.717, 95% CI 0.580-0.888, p = 0.002, respectively), and older age at diagnosis showed a lower risk for developing perianal fistula (RR 0.661, 95% CI 0.439-0.995, p = 0.047). Furthermore, ileal involvement was associated with a lower risk for perianal fistula (RR 0.713, 95% CI 0.561-0.906, p = 0.006), a lower risk for any fistula (RR 0.709, 95% CI 0.558-0.901, p = 0.005), and a higher risk for stenosis (RR 2.170, 95% CI 1.728-2.725, p < 0.001). Key Messages: In the nationwide SIBDCS, younger age at diagnosis and male gender were risk factors for developing perianal and nonperianal fistulae. Additionally, ileal involvement was revealed to be a potent risk factor (RR 2.170) for developing a stenosis.

Keywords:
Crohn disease, Fistula, Inflammatory bowel disease, Risk factors, Stenosis
1.
Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
2.
Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002;347:417-429.
3.
Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B: Hospitalisations and surgery in Crohn's disease. Gut 2012;61:622-629.
4.
Rieder F: The gut microbiome in intestinal fibrosis: environmental protector or provocateur? Sci Transl Med 2013;5:190ps10.
5.
Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-880.
6.
Baert F, Caprilli R, Angelucci E: Medical therapy for Crohn's disease: top-down or step-up? Dig Dis 2007;25:260-266.
7.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-667.
8.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Pare P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators: Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-1834.
9.
Schoepfer AM, Vavricka S, Safroneeva E, Fournier N, Manser C, Frei P, Deltenre P, Rogler G, Straumann A, Ezri J, Nydegger A, Braegger C: Systematic evaluation of diagnostic delay in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2017;64:245-247.
10.
Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S: Bowel damage as assessed by the Lémann index is reversible on anti-TNF therapy for Crohn's disease. J Crohns Colitis 2015;9:633-639.
11.
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ: The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-297.
12.
Nielsen OH, Rogler G, Hahnloser D, Thomsen OO: Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009;6:92-106.
13.
Sato Y, Matsui T, Yano Y, Tsurumi K, Okado Y, Matsushima Y, Koga A, Takahashi H, Ninomiya K, Ono Y, Takatsu N, Beppu T, Nagahama T, Hisabe T, Takaki Y, Hirai F, Yao K, Higashi D, Futami K, Washio M: Long-term course of Crohn's disease in Japan: incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery. J Gastroenterol Hepatol 2015;30:1713-1719.
14.
Felley C, Mottet C, Juillerat P, Froehlich F, Burnand B, Vader JP, Michetti P, Gonvers JJ: Fistulizing Crohn's disease. Digestion 2005;71:26-28.
15.
Hanauer SB, Smith MB: Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993;88:646-649.
16.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
17.
Korelitz BI, Present DH: Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985;30:58-64.
18.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885.
19.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV: Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406-1417.
20.
Cohen RD: The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:1603-1609.
21.
Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA: Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther 2009;30:757-766.
22.
Bataille F, Klebl F, Rummele P, Schroeder J, Farkas S, Wild PJ, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G: Morphological characterisation of Crohn's disease fistulae. Gut 2004;53:1314-1321.
23.
Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G: Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis 2008;14:1514-1527.
24.
Scharl M, Weber A, Furst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M, Rogler G: Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflamm Bowel Dis 2011;17:1907-1916.
25.
Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Ruhl A, Rogler G: Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae. Gut 2013;62:63-72.
26.
Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, Scharl M: A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn's disease-associated fistulae. Inflamm Bowel Dis 2013;19:2878-2887.
27.
Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Ruhl A, Fried M, Rogler G, Scharl M: The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae. PLoS One 2013;8:e78882.
28.
Kruis W, Scheuchenstein AM, Scheurlen C, Weinzierl M: Risk factors for the development of fistulas in Crohn disease. Z Gastroenterol 1989;27:313-316.
29.
Rieder F, Fiocchi C: Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009;6:228-235.
30.
Rimola J, Planell N, Rodriguez S, Delgado S, Ordas I, Ramirez-Morros A, Ayuso C, Aceituno M, Ricart E, Jauregui-Amezaga A, Panes J, Cuatrecasas M: Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. Am J Gastroenterol 2015;110:432-440.
31.
Dotan I: Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig Dis 2009;27:206-211.
32.
Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP; Swiss IBD Cohort Study Group: Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009;38:922-931.
33.
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-250.
34.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-1794.
35.
Polito JM 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM: Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-586.
36.
Martin TD, Chan SS, Hart AR: Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci 2015;60:1396-1405.
37.
Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP: The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008;23:1213-1221.
38.
Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J: Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009;15:734-741.
39.
Hanauer SB, Stromberg U: Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-388.
40.
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Soderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J; European Crohn's and Colitis Organisation (ECCO): The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101.
41.
Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB: Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-1206.
42.
Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok RC: The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010. Am J Gastroenterol 2014;109:409-416.
43.
Nuij VJ, Fuhler GM, Edel MJ, Ouwendijk RJ, Rijk MC, Beukers R, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ: Benefit for earlier anti-TNF treatment on IBD disease complications? J Crohns Colitis 2015;9:997-1003.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.